Main > ONCOLOGY (**) > Kidney Cancer>RCC>Post Surgery>

---

Intermediate-High or High Risk R or Post
Surgery & Resection of Metastatic Lesions>Adjuvant Treat.>PD-1 MAb

Kidney Cancer>RCC>Post Surgery>'s subsections
(*) EU CE Mark Date: 2022. 01.27.
(*) USA Approval Date: 2021. 11.18
Company
Generic Name: Pembrolizumab
RTM
RTM Web-Site

Kidney Cancer>RCC>Post Surgery>'s products
This section has no products